Health
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate – BioSpace
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19…
Sanofi and GSK initiateglobal Phase 3clinical efficacy study of COVID-19 vaccinecandidate
- Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants
- A booster study program will begin in the coming weeks to complement Phase 3 trial
- Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment…
Continue Reading
-
Noosa News15 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News13 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News23 hours agoDifficult to diagnose and potentially deadly — this lesser-known disease is becoming more common